PRDL IPO: Medical Device Manufacturer Prodia Offers 30% of Stake, Targeting Rp62.7 Billion in Funds

Amid the growth of the healthcare industry and the increasing demand for diagnostic devices in Indonesia, PT Prodia Diagnostic Line Tbk (PRDL) has officially announced plans for an Initial Public Offering (IPO).

The company, which operates as a manufacturer of medical devices—specifically In Vitro Diagnostics (IVD)—will issue 522.9 million new shares, equivalent to 30% of its post-IPO capital.

With an offering price range of Rp100 to Rp120 per share, PRDL aims to raise up to Rp62.7 billion. The public offering is scheduled to take place in early July 2026, with the company set to be listed on the Indonesia Stock Exchange (IDX) on July 9, 2026. 

Key Takeaways

• PRDL offers 522.9 million shares with a price of IDR 100–IDR 120 per share, it has the potential to raise a maximum of IDR 62.75 billion to pay off debt and expand the business.
• Most of the IPO funds will be allocated for repayment of bank credit (around Rp. 35.67 billion) and capital expenditure to expand the production capacity of diagnostic tools.
• Listing di BEIscheduled onJuly 9, 2026with underwriter PT Sucor Sekuritas; this is a subsidiary of the Prodia Group which has positive growth performance in 2025.

Register at Bittime now and start trading crypto with a fast, secure, and easy process in the app.

PRDL Company Background

PT Prodia Diagnostic Line Tbk is a medical device manufacturer focused on the development and production of In Vitro Diagnostic (IVD) products. 

Its product portfolio includes devices and reagents for clinical chemistry, hematology, immunology, and molecular biology testing, as well as other medical diagnostic instruments.

The company is part of the Prodia Group, one of Indonesia’s leading healthcare groups, which also owns PT Prodia Widyahusada Tbk (PRDA) as its primary entity in the clinical laboratory sector. 

Additionally, PRDL has a partnership with Germany-based diasys Diagnostic Systems GmbH, which holds a 10% stake in the company.

PRDL’s distribution network covers more than 370 regencies and cities throughout Indonesia, demonstrating a fairly extensive reach for medical devices.

In 2025, PRDL’s financial performance showed solid growth. Revenue rose 26.79% to Rp74.3 billion, while net income surged nearly 70% to Rp16.9 billion. Total assets as of the end of 2025 stood at Rp194.4 billion, with equity of Rp83 billion.

Read also: What Is NBIS Stock? Nebius and CoreWeave Shares Soar After Entering the Nasdaq-100

PRDL IPO Share Offering Details

ToFollowing are the main details of PRDL's initial public offering:

• Number of shares offered: Maximum 522.9 million new shares
• Percentage: 30% of issued and fully paid capital after IPO
• Bid price: Rp100 – Rp120 per share
• Target funds: Up to Rp. 62.75 billion (assuming the highest price)
• Nominal value: Rp50 per share
• Underwriter: PT Sucor Securities

In addition, there is an employee stock allocation of a maximum of 36.603 million shares or approximately 7% of the shares offered.

Read also: What Sectors Does BUMI Stock Move In?

PRDL IPO Complete Schedule

Next is the PRDL IPO timeline based on the initial prospectus:

• Initial Offer Time: 18 – 23 June 2026
• Effective Estimate from OJK: 29 June 2026
• Public Offering Period: 1 – 7 July 2026
• Rationing: 7 July 2026
• Share Distribution: 8 July 2026
• Listing on the IDX: July 9, 2026

Investors who wish to participate in this IPO can place orders through securities that are members of the underwriters or brokers who collaborated with Sucor Securities during the public offering period.

Read also: Tokenized Stocks Are Gaining Popularity, Crypto Liquidity Is Shifting

Planned Use of IPO Proceeds

PRDL has set out a fairly clear allocation of funds from the IPO proceeds (after deducting issuance costs):

• Rp. 35.67 billion— for repayment of principal loans to PT Bank Central Asia Tbk (BCA) and PT Bank Pan Indonesia Tbk (Panin Bank).
• Around 28.92%— for capital expenditure, including the addition of machines, calibration equipment, software, vehicles, and the development of production facilities such as the Biomolecular Lab AHU.
• Around 8.51% — for working capital, including purchasing raw materials, product development, and marketing activities.

This strategy shows that management wants to strengthen the capital structure while expanding production capacity to support future business growth.

Read also:DSSA Shares Are Flying High Not Because of Coal, Here's the Reason

Business Prospects and Opportunities for Investors

The medical device industry in Indonesia, particularly the IVD segment, has quite promising prospects along with increasing health awareness, population growth, and government programs in the health sector.

As a subsidiary of the Prodia Group, which already has strong brand recognition in the diagnostics sector, PRDL has advantages in terms of distribution network and local market understanding. Significant profit growth by 2025 is also a positive signal for investors seeking new issuers in the healthcare sector.

However, investors should also note that this is an IPO stock with a relatively small capitalization, so the potential for price volatility after listing is quite high.

Read also: How to Invest in Global Stocks with Small Capital Through Tokenized Stocks

Risks to Consider

As with any IPO, there are several risks mentioned in the prospectus, including:

• Dependence on government health sector spending
• Potential low stock liquidity after listing
• Competition in the medical device industry
• Operational and regulatory risks in the healthcare sector

Investors are advised to read the prospectus thoroughly before making an investment decision.

Keep tracking other stock tokens such as AMZON, AMDON, and NFLXON as well as MSFTON, then you can start trading on the trusted exchange, only on Bittime.

Conclusion

PRDL’s IPO is one of the most attractive initial public offerings in the first half of 2026, particularly for investors interested in the healthcare and diagnostic equipment sectors.

With a fundraising target of Rp62.7 billion, a 30% share offering, and a plan to use the proceeds primarily for debt reduction and capacity expansion, PRDL demonstrates a commitment to strengthening its business fundamentals.

For retail investors wishing to participate, it is important to monitor the public offering schedule from July 1–7, 2026, and conduct a thorough analysis of the prospectus that has been released. As always, investment decisions should be based on independent research and each investor’s individual risk profile.

If you are interested in following the progress of this IPO, be sure to stay updated through the official websites of the Indonesia Stock Exchange (BEI), Sucor Sekuritas, or your trusted securities platform.

Interested in investing in global stocks? Check out tokenized stocks like AAPLX and NVDAX on the Bittime market.

Bittime is a licensed and regulated Digital Financial Asset Trader (PAKD) supervised by Indonesia’s Financial Services Authority (OJK) — where you can buy Bitcoin in Indonesia and hundreds of other crypto assets starting from just Rp10,000. The registration process is fast, secure, and you can get started today.

Track USDT to IDR conversions and monitor your favorite crypto assets in real time. Everything is available in one crypto investment app that you can download for free on the Play Store

Ready to start? Register now on Bittime and execute your investment strategy with a platform trusted by millions of users in Indonesia.

FAQ

What is PRDL and its core business?

PT Prodia Diagnostic Line Tbk (PRDL) is a manufacturer of medical devices, specifically in vitro diagnostic (IVD) products, such as reagents and instruments for medical laboratory examinations. The company is a subsidiary of the Prodia Group.

What is the PRDL IPO share offering price?

PRDL's offering price is between Rp100 and Rp120 per share. With 522.9 million shares on offer, the maximum potential proceeds are Rp62.75 billion.

When is the PRDL stock listing schedule on the IDX?

PRDL shares are planned to be listed on the Indonesia Stock Exchange onJuly 9, 2026The public offering period runs from July 1–7, 2026.

Where will the PRDL IPO proceeds be used?

Most of the funds will be used to pay off bank debt (around IDR 35.67 billion), the remainder for capital expenditure (machinery and production facilities) and the company's working capital.

How to follow PRDL IPO?

Investors can place stock orders through securities underwriters (Sucor Securities) or collaborating brokers during the public offering period in early July 2026. Ensure you have an active securities account.